International Drug Company Bribes: Large Financial Rewards Are Being Offered to People That Expose Drug Company Bribes to Public Officials by International Whistleblower Reward Lawyer Jason S. Coomer
The Foreign Corrupt Practices Act (FCPA) prohibits bribery of foreign
officials by U.S. and foreign companies listed on the U.S. securities
exchange. These prohibitions include large drug companies that are paying bribes to doctors, health care administrators, and other government officials to sell drugs and obtain large procurement contracts in China, Russia, and other pharmerging countries.
Foreign Corrupt Practices Act Whistleblowers that properly
report violations of the FCPA by a U.S. or foreign company listed on the
U.S. securities exchanges can recover a large reward for exposing FCPA
violations. These whistleblowers can expose bribery schemes through a
lawyer and protect their identify.
For more information on Exposing Drug Company Bribes, please go to the following website:
International Whistleblower Rewards.
Between $100 Billion to $200 Billion in Corrupt Drug Procurement Contracts Are Obtained Each Year Through Fraud and Corruption
Every year over $4.1 trillion (US dollars) is spent worldwide on health
services including approximately $800 billion (US dollars) that is spent
in the pharmaceutical market on drugs and medications. It is estimated
that approximately 10 to 25% of public health care procurement spending
including drug contracts, medicines, pharmaceuticals, medical equipment,
and medical devices is lost to corrupt and fraudulent acts. These acts
include government official bribes, illegal kickbacks, and other
illicit payment and fraud schemes.
The World Health Organization (WHO) defines the term "medicines chain"
to be the steps that are required for the creation, regulation,
management and consumption of pharmaceuticals. In other words it is the
medication supply chain in the pharmaceutical industry from creation to
end user. According to the World Health Organization, corruption is
common in the international pharmaceutical sector and occurs throughout
all stages of the medicines supply chain, from research and development
to dispensing and promotion. These unethical and corrupt practices in
the medicines supply chain can take many forms such as falsification of
evidence, false certification of adulterated drugs, import false
certifications, export false certifications, conflicts of interest, and
illegal bribe and kickback schemes.
As such, the World Health Organization and many other international
public health organizations are seeking public policy changes under the
umbrella of good governance initiatives within the medicines chain to
reduce government corruption and optimize public health outcomes. Some
proposed public policy changes that can help reduce corruption and fraud
in the pharmaceutical medicines chain include: 1) protection of
international medicines supply chain whistleblowers; 2) offering
financial incentives to international medicines chain whistleblowers; 3)
passage of legislation and regulation for drug quality control and
official certifications to monitor the transport of medications
including the export and import of medicines throughout world and along
international medicines supply chains; 4) increased enforcement
mechanisms for violations of existing pharmaceutical laws and
regulations; and 5) increased resources for conflict of interest
management and checks to ensure key people in the medicines chain are
not accepting illegal bribes, kickbacks, and other illicit payments.
In response to these good governance initiatives, the international
community including the United States, United Kingdom, and many other
countries have enacted new anti-bribery and anti corruption laws that
will enable persons with knowledge of international medicines supply
chain fraud and corruption to expose the illegal acts and reap rewards
from blowing the whistle, while being protected from potential
retaliation from the wrong doers.
While there are an increasing number of reported cases of corruption in
the medicines chain, much unethical practice has historically gone
unreported. This is changing as new whistleblower protections and
whistleblower financial incentives are coming into place to help
overcome institutionalized corruption in the pharmaceutical medicines
chain and to provide protection for courageous whistleblowers that want
to change the institutionalized corruption that is damaging their
countries.
Because medicines typically change hands several times in the medicines
chain between the drug manufacturer and patients, the large number of
steps in the medicines chain allows numerous opportunities for unethical
practices to take place. Therefore increased regulations and laws
throughout the medicines chain including manufacturing quality
assurances, export regulations and inspections, import regulations and
inspections, health care provider regulations and inventory policies,
and patient protections are needed. Fortunately, the new international
whistleblower laws will allow international whistleblowers with
specialized knowledge of the corruption to blow the whistle on fraud,
false certifications, and illicit payments that are occurring throughout
the medicines chain.
A lack of transparency and accountability within the medicines chain can
also contribute to unethical practices and corruption. Therefore
increased enforcement mechanisms are needed for violations of existing
pharmaceutical laws and regulations. These enforcement mechanisms
include "SEC Bounty Actions" that allow private citizens to work through
international medicines supply chain whistleblower reward lawyers to
expose significant fraud and obtain large bounties for successful
prosecution of pharmaceutical illicit payment schemes. Ideally, these
international medicines supply chain whistleblower reward actions will
track fraud and corruption to the root causes and help reform corporate
corruption of public health care systems. Through international
pharmaceutical representative whistleblowers, international drug
executive whistleblowers, foreign government official whistleblowers,
health care provider whistleblowers, and other medicines supply chain
whistleblowers, the international community can efficiently identify,
expose, and remedy medicines chain corruption.